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Sublingual immunotherapy (SLIT) use in the United States to date has been limited, despite common use and
demonstrated efficacy elsewhere in the world. This is largely in part due to lack of FDA-approved SLIT products,
lack of established dosing and administration guidelines, and cost concerns. Several recent studies have demonstrated
efficacy and safety of two sublingual grass tablets and one ragweed tablet approved by the FDA, and one sublingual
ragweed liquid currently pending FDA approval. With FDA approved SLIT products, there will be numerous challenges
to the allergist and patient in deciding whether to pursue SLIT or SCIT (subcutaneous immunotherapy) for allergic
rhinitis. This review highlights the current state of SLIT in the United States, and expected future directions.
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Sublingual immunotherapy (SLIT) is commonly used in
many parts of the world, but use in the United States to
date has been limited. There have been numerous SLIT
studies performed to date, but, until recently, only a small
number have been double-blind, placebo-controlled. This
review sought to focus on the current state of SLIT in the
United States, and expected future of SLIT pending Food
and Drug Administration (FDA) approval of sublingual
therapies.Current immunotherapy use in the United States
In 2011, a survey of practicing allergists in the American
College of Allergy, Asthma, and Immunology (ACAAI)
[1] showed that 11.4% of respondents were commonly
using SLIT, compared to 5.9% in a 2007 survey [2]. 90.2%
of respondents in the 2011 survey found lack of FDA ap-
proval for SLIT products to be the primary barrier to SLIT
use in the United States. Other barriers included lack of
established practice parameters, unknown effective dose,
inadequate training or experience, cost, dose required, and
adverse effects. SLIT was felt to be safer than subcutane-
ous immunotherapy (SCIT) by 66.7% of respondents.
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article, unless otherwise stated.administration of SLIT, practitioners using SLIT have had
to use other commercially available products, primarily
extracts available for SCIT (86%). A majority (76.5%) of
those using SLIT used multiple allergen extracts in all or
at least half of their patients, versus only 23.5% using
monotherapy in all or at least half of patients. 80% of
physicians using SLIT required at least 1 dose to be ad-
ministered in the office, and of those, 67% required only
the first dose to be given in the office. Only 13.3% required
3 or more doses to be done in an office setting before
home use. In terms of effectiveness, no physicians felt it
was not effective at all. 56.9% felt SLIT was less effective
that SCIT, though 31.4% thought the two were equally
effective. 11.8% felt SLIT was more effective.
The Allergies, Immunotherapy & Rhinoconjunctivitis
Survey (AIRS) [3] surveyed both patients and health care
providers during a 2-month period in 2012. Patients
were eligible if they were 5 years of age or older, had a
diagnosis of hay fever, allergic rhinitis, rhinoconjunctivitis,
or nasal or eye allergies, and either had symptoms or
medication use in the prior 12 months. Providers were
eligible if they provided direct patient care to patients
with allergies in an outpatient setting at least weekly.
2765 patients and 500 providers completed the survey.
Patients were taken from a national probability sample
screened for a geographic stratification sampling over
43,000 households in the US. Providers were multidiscip-
linary, including practitioners of allergy, family medicine,entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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In addition to physicians, nurse practitioners and physician
assistants were surveyed as well. The primary reason that
practitioners across the board recommended immunother-
apy to both children and adults was lack of efficacy of
other therapies. When asked if the immunotherapy recom-
mended was subcutaneous or sublingual (Figure 1), re-
sponses varied greatly by specialty. 97% of allergists
recommended subcutaneous, whereas 2% recommended
both, and 1% recommended neither [4]. All practitioners
recommended subcutaneous more often than sublingual,
though ophthalmologists (26%) and otolaryngologists (21%)
were more likely to recommend SLIT than other providers.Difficulty getting FDA approval
FDA approval has been difficult because SLIT studies
differ from allergy and asthma medication studies in
terms of population selection, symptom variance, and
exposure variance. In all medication studies, there is
population variation to account for, but SLIT studies
must account for variation in allergen exposure as well.
Unlike studies for allergic rhinitis medications, patients
are not symptomatic prior to treatment. Furthermore,
pollen levels vary, which will affect the degree of symptoms
seen during a study.
Total composite scores (TCS) to assess improvement
from SLIT for allergic rhinitis and rhinoconjunctivitis rely
on symptom improvement and decreased medication use
to prove effectiveness. Symptom scores are generally
based on standardized scoring symptoms evaluating nasal
and ocular symptoms. Scores to evaluate medication use,
however, vary by study without standardized norms to
make effective comparisons across studies. This lack ofFigure 1 4 Providers’ immunotherapy prescribing practices. Prescribing
of provider’s specialty. NP/PA (Nurse Practitioners/Physician Assistants).standardized composite score makes interpretation of
SLIT studies more complicated.
Medication studies generally require a statistically signifi-
cant change in the study group from control (p < 0.05) to
prove efficacy, but, according to the FDA, that is not
enough to prove a true clinical meaningful change in SLIT
studies. The FDA requires that studies demonstrate
10% efficacy above the 95% confidence interval in mean
TCS difference versus placebo and at least a 15% improve-
ment in TCS compared to placebo. Other organizations
have suggested at least a 20% improvement in TCS ver-
sus placebo, as recommended by the World Allergy
Organization [5].
Sublingual immunotherapy products
Currently, the extracts being used by practitioners for sub-
lingual immunotherapy are commercially available extracts
used for SCIT in the US. SLIT tablets for northern pasture
grasses and ragweed are approved by the FDA for use In
the US. Results of clinical trials addressing safety and
efficacy of these products, as well as of a ragweed sub-
lingual liquid currently pending FDA approval, are
summarized in Table 1.
Several clinical trials have evaluated the safety and effi-
cacy of timothy grass SLIT tablets. The largest clinical trial
to date [6] evaluated the safety when only the first dose of
timothy grass tablet immunotherapy was given in the phy-
sician’s office. Prior North American studies in both adult
and pediatric populations [7,8] evaluated safety when the
first three doses were administered in the physician’s of-
fice, without evidence of an additional safety advantage.
Subjects for the most recent clinical trial were 5 to 65 years
of age, with history of grass pollen-induced allergic rhinitis
(AR) or allergic rhinoconjunctivitis (ARC), with or withoutpractices of subcutaneous and sublingual immunotherapy as a function






















76.9% • Compared to placebo, the
treatment group had at 20%
improvement in TCS.
• The most common AEs were oral
pruritus, throat irritation, ear
pruritus, and upper respiratory tract
infections.
• DSS improved by 18% and RQLQ by
17% in treatment group versus placebo.
DMS improved by 26%.
• There were no serious AEs or
anaphylactic reactions.
• There was 1 patient in the
treatment group that received








89% • TCS improved 26% in treatment group
versus placebo.
• Common AEs included oral
pruritus, throat irritation, and
mouth irritation.
• DSS improved 25%, DMS improved 81%,
and RQLQ improved 18% over placebo.
• A moderate reaction of lip
edema, dysphagia, and cough was
reported by one patient, which
responded to epinephrine. It was









85% • MK-7243 provided a 20% lower DSS
during peak and entire GPS, 38% lower
DMS during peak season, 35% lower
DMS during entire GPS, and 32% lower
TCS during entire GPS compared to
placebo.
• The most common AEs were
throat irritation, oral pruritus or
paresthesias, mouth edema, and
ear pruritus.
• Systemic reactions occurred in 2
MK-7243 patients, were moderate
in severity, and resolved without
treatment.
• There were no severe systemic







77.9% • Those in the treatment group had a
significantly lower CS during the peak
pollen season than the placebo group,
with a relative decrease in 28.2%.
• Common AEs included oral
itching, throat irritation, and
nasopharyngitis.
• The benefit was most notable in those
with baseline detectable serum IgE to
timothy grass.
• There were no anaphylactic








85% • During the peak ragweed season, the 6-
Amb a 1 unit group and 12-Amb a 1 unit
group had a 21% and 27% reduction in
TCS compared to placebo, respectively.
• The most common AEs were oral
pruritus, throat irritation, swollen
tongue, and ear pruritus.
• During the entire ragweed season, the
6- Amb a 1 unit group and 12-Amb a 1
unit group had a 16% and 26%
reduction in TCS compared to placebo,
respectively.
• There were no serious treatment-
related AEs.
• One treatment patient received








83.9% • The treatment group had a 43%
reduction in TCS during the entire
ragweed season compared to placebo.
• The most frequently reported
treatment-related AEs were
oromucosal reactions, which
occurred early and were transient.
• This was statistically significant after
adjusting the 95% confidence interval to
account for 20% clinically meaningful
difference over placebo.
• There were no systemic reactions,
anaphylaxis, or death in the
treatment group.
TCS Total Combined Score, DSS Daily Symptom Score, DMS Daily Medication Score, RQLQ Rhinoconjunctivitis Quality of Life Questionnaire, AEs Adverse events,
GPS Grass pollen season, CS Combined Score.
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during the previous grass pollen season (GPS), have a
positive skin prick test to Phleum pratense (≥5 mm wheal)
and/or specific IgE against Phleum pratense (≥0.7 kU/L).
FEV1 had to be ≥ 70% of predicted value. There were no
significant differences in baseline demographic character-
istics between the placebo and treatment groups. The
majority (85%) of each group was polysensitized to other
aeroallergens besides grass. Total combined scores (TCS)
were determined during peak GPS and 16 weeks prior,
using combination of Daily Symptom Score (DSS) and
Daily Medication Score (DMS), which factored in use of
oral antihistamines, ophthalmic antihistamines, intranasal
steroids, and oral steroids. Those receiving timothy grass
tablets had 20% lower DSS than placebo during both the
peak GPS and entire GPS (Figure 2). They also had 38%
and 35% lower DMS during peak and entire GPS, respect-
ively. The TCS for the entire season was 23% lower in the
treatment group. These were similar to rates found in prior
studies by Nelson et al. [7] and Blaiss et al. [8] When exam-
ined exclusively in children age 5–17 years, the TCS was
32% lower in the treatment group during the entire GPS.
The most commonly reported adverse event in both the
grass AIT and placebo groups was throat irritation (24%
and 4% of subjects, respectively). Other common adverse
events were oral pruritus, oral paraesthesia, mouth edema,
and ear pruritus. Systemic allergic reactions were rare in
the studies.Figure 2 6 Daily symptom and medication scores with timothy grass
score (DMS) over the entire and peak grass pollen season (GPS). *Medians are
differences in DSS for MK-7243 vs placebo were −0.64 over the entire GPS an
MK-7243 vs placebo were −0.48 over the entire GPS and −0.62 over the peakA study addressing the clinical efficacy and safety of a
300 index of reactivity (IR) 5-grass pollen sublingual tablet
was performed in adults in the United States [9]. 473
subjects with documented grass pollen allergy by history
and positive skin test and Rhinoconjunctivitis Total Symp-
tom Score of 12 or greater (scale 0–18) during the prior
grass pollen season were randomized in a double-blind,
placebo-controlled trial to receive 300IR 5-grass sublin-
gual tablet or placebo starting 4 months prior to the
pollen season and continuing through the season. Efficacy
was determined using a combined score (CS) that took
into account both daily symptoms and medication use.
The treatment group had significantly lower CS scores
during the peak pollen season than the placebo-treated
group. Patients also had serum specific IgE and IgG4 to
timothy grass measured at baseline, at the midpoint of the
pollen season, and at the end of the season. Patients with-
out measurable baseline specific IgE to timothy grass
showed no difference between placebo and active treat-
ment. In patients with measurable serum specific IgE to
timothy grass, those treated with 300IR had an increase in
IgE over the course of the pollen season, while those
treated with placebo remained relatively unchanged.
Similarly, timothy grass serum IgG4 increased in the
treatment group but remained unchanged in the placebo
group. Figure 3 shows daily CS as a function of serum
specific IgE to timothy grass, demonstrating that patients
with undetectable IgE had little difference betweensublingual tablet. Daily symptom score (DSS) and daily medication
reported for DSS, and means are reported for DMS. Between-treatment
d −0.69 over the peak GPS. Between-treatment differences in DMS for
GPS.
Figure 3 9 Daily combined scores with 300 IR 5-grass sublingual tablet as a function of specific IgE. Daily CS overall and in sub-groups
based on timothy grass-specifc serum IgE at baseline. The number of participants in each group is displayed in each bar. Note: IgE data were not
obtained for 1 placebo-treated subject. *P < .001 versus placebo.
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tion of serum specific IgE to timothy grass, and not just a
positive allergy skin test, may be an important determin-
ant in deciding who is a good candidate for treatment,
though per FDA labeling the only requirement is either a
positive skin test or blood study for all SLIT products. Fre-
quently reported adverse events were mild, including oral
itching, throat irritation, and nasopharyngitis. There were
no episodes of anaphylaxis, and no treatment-related ser-
ious adverse events.
A study by Nolte et al. evaluating a sublingual rag-
weed immunotherapy tablet [10] showed that subjects
treated with 6 units of Amb a 1 and 12 units of Amb a 1
both showed decrease in TCS compared to placebo.
Though there was no significant difference between the
two, a more pronounced clinical efficacy was noted with
the 12 Amb a 1 unit dose (Figure 4). Similarly, bothFigure 4 10 Total combined scores for ragweed sublingual tablets ver
AIT indicates allergy immunotherapy tablet.showed decrease compared to placebo in oral antihista-
mine, ocular antihistamine, and nasal corticosteroid use
with a slightly larger decrease in medication use in the
12 units of Amb a 1 group compared to the 6 unit
group. Changes in TCS during peak and entire pollen
season were similar. In patients rating symptoms using
a visual analogue scale, there was significantly better
improvement with the 12 versus 6 Amb 1 unit dose
compared to placebo. Adverse events were mild and
generally involved oropharyngeal itching or discomfort.
One patient did receive epinephrine for sensation of
pharyngeal edema.
Creticos et al. [11] performed a phase 3, randomized
double-blind, placebo-controlled parallel trial of standard-
ized short ragweed (RW) sublingual allergy immunother-
apy liquid (SAIL) for allergic rhinoconjunctivitis in North
America. Subjects, aged 18–55 years, with or withoutsus placebo. Total combined score (TCS) plotted against pollen count.
Table 2 Pros and cons for prescribing auto-injectable epinephrine for SLIT
Pros Cons
● There is a slight, though rare risk for anaphylaxis. ● Adverse reactions with SLIT are generally mild, and systemic reactions
are generally not severe, with no deaths reported.
● SLIT is a home-based therapy without anaphylaxis-trained practitioners
available should a reaction occur
● Auto-injectable epinephrine may be used incorrectly or inappropriately
by patients.
● There are medical-legal concerns if a patient should have a reaction
at home without having an auto-injector prescribed.
● Auto-injectors are not required for SLIT in Europe and Canada. Many
US practitioners do not require them for SCIT patients.
● Costs of epinephrine autoinjectors
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a 2 year history of moderate to severe rhinoconjunctivitis
secondary to ragweed) and positive skin prick test to short
ragweed. Subjects self-administered RW-SAIL or placebo
(in a 1:1 ratio) starting 8–16 weeks prior to the 2011 RW
season, and continued through the season. The SAIL
group had incremental increase in doses at beginning of
the study, starting with placebo, 18 micrograms Amb a 1,
and then 50 micrograms Amb a 1, and continued the
highest tolerated dose through the rest of the season.
Subjects maintained daily symptom and rescue medication
e-diaries. Efficacy endpoints included total combined symp-
tom + medication scores (TCS), daily symptom scores
(DSS), IgG4 and IgE ragweed-specific antibody. Safety was
evaluated by adverse event diaries, laboratory evaluation,
and physical examinations. During the entire season, there
was a 43% decrease in TCS in the RW-SAIL group com-
pared to placebo. Similarly, there was a 42% decrease in
TCS during peak season, and decrease in DSS during entire
(42%) and peak (41%) seasons in the RW-SAIL group com-
pared to placebo. 94% of patients in the treatment group
tolerated the maximum dose (50 micrograms of Amb a 1),
with 6% remaining on, or stepping down to, the lower dose
of 18 micrograms. There were no systemic reactions,
anaphylaxis, or deaths in the RW-SAIL group. The most
common treatment emergent adverse effects (AEs) were
headache, upper respiratory symptoms, and gastrointestinal
symptoms. The most frequent treatment-related AEs were
oromucosal reactions, which occurred early and were tran-
sient. There were no significant findings on laboratory
monitoring, aside from one patient with hematuria that
was deemed not related to the treatment. One patient in
the RW-SAIL group had angioedema of the hand after
touching a household cleaner, that was treated with epi-
nephrine in the emergency department. It was judged not
likely related to the study drug.
Other concerns
There has been considerable focus on safety of SLIT versus
SCIT and what this means for the patient and clinicians
alike. One of the potential benefits of SLIT is that it is
home-based therapy due to the excellent safety profile,
which may increase adherence and convenience forpatients. There have no deaths reported with SLIT home
use throughout the world. Clinical trials in the US, as dis-
cussed, have found systemic reactions to be rare. When sys-
temic reactions do occur, they are generally mild or
moderate in nature, and not life-threatening. In fact,
most reactions resolve without treatment. Due to this,
there is ongoing debate over whether patients on SLIT
would require epinephrine auto-injectors. Table 2 shows
the pros and cons of patients having an epinephrine auto-
injector for SLIT.
Dosing of the approved SLIT tablets is different than
what US clinicians are used to doing with SCIT. For the
5-grass tablet, the FDA label states to start 16 weeks be-
fore the start of the grass season and continue through
the season, while the timothy grass tablet and ragweed
tablet begin12 weeks before the start of the appropriate
season and continue through that season. Also, the timothy
grass tablet has a second dosing schedule year- round for
3 years for sustained effectiveness.
There are multiple cost concerns for both the patient and
clinician as well. FDA-approved SLIT will be a prescription
benefit, and coverage may be dramatically different than
coverage for SCIT, which is a procedure prepared and billed
for by an allergist. Cost of therapy, whether through insur-
ance or out-of-pocket, will likely contribute significantly to
adherence as well. González-De-Olano et al. [12] looked at
adherence prior to and during a recent Spanish recession,
and showed a significant decrease in both SCIT and SLIT
use during the recession. Ongoing changes in the health-
care system in the United States may cause changes in IT
coverage across the board, whether SLIT or SCIT. This
may provide new challenges when making the choice
between therapies, and will have to be taken into consider-
ation as these changes become evident.
Lastly, adherence to therapy and persistence with therapy
is a concern for home-based therapy as well. Patients
receiving SCIT have observed therapy, and practitioners
know when patients are not receiving their shots. Adher-
ence to home-based SLIT is more difficult to monitor. A
retrospective chart review of patients in a US allergy prac-
tice utilizing both SCIT and SLIT showed that only 32.5%
of all patients completed the entire treatment course de-
fined as 3 years, 35% of SCIT patients and 23.7% of SLIT
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average of 3.6 years, compared to 2.6 years for SLIT
patients.
Conclusions
Several double-blind, placebo-controlled, randomized con-
trol trials have been performed in North American for the
different forms of SLIT being reviewed for approval by the
FDA. These studies have demonstrated clinical effectiveness
in terms of symptom and medication scores, with low
incidence of adverse effects. In general, adverse effects of
SLIT have been mild, with the most common adverse
effects being oromucosal itching, swelling, or pain.
Assuming SLIT treatments are approved in the US, there
are numerous challenges on the horizon for allergists and
other practitioners. It is unclear if clinicians will use
approved SLIT therapies, continue to mix their own SLIT
from SCIT extracts, or only use SCIT. SLIT is a promising
option for monosensitized and some polysensitized pa-
tients, those that refuse injections, especially children, and
patients that can not come regularly to a clinician’s office
for injections. SCIT may continue to be a superior option
for some polysensitized patients, particularly when sensi-
tized to aeroallergens for which approved SLIT treatments
are not available. Monitoring of adherence to therapy
would be more difficult with SLIT compared to SCIT, but
a home-based therapy not requiring weekly office visits
may actually improve patient adherence.
There are financial aspects to consider as well. SCIT is a
billable procedure, whereas SLIT would be a prescription.
Changes in the current healthcare system in the United
States may affect coverage of both SCIT and SLIT. Depend-
ing on the patient’s insurance coverage, one modality of
immunotherapy may be more financially favorable to the
patient, which will likely lead to its use for that patient.
Lastly, allergists may face a change in income should SLIT
become common practice, with the loss of profit from
SCIT procedure billing. However, SLIT may grow the
allergist’s practice, as more patients may be receptive to a
home immunotherapy program. All of these concerns will
be have to taken into consideration as FDA-approved
SLIT therapies become available.
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